On Monday, Inspire Medical Systems earned an upgrade to its Relative Strength (RS) Rating, from 79 to 84.
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buy zone in heavy volume.
Inspire Medical Systems reported 0% EPS growth last quarter, while sales growth came in at 30%. The company is expected to report its latest numbers on or around Nov. 4.
The company earns the No. 18 rank among its peers in the Medical-Products industry group. Bioventus, Insulet and ResMed are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
